BioLine RX Ltd (BLRX) — Cash Flow-to-Debt Ratio
BioLine RX Ltd (BLRX) has a Cash Flow-to-Debt Ratio of -0.10x as of September 2025, meaning its operating cash flow of ILA-2.11 Million could theoretically repay 0% of its total liabilities (ILA20.27 Million) in one year. See BioLine RX Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioLine RX Ltd Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for BioLine RX Ltd across 15 annual periods. Also explore BioLine RX Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioLine RX Ltd (2010–2024)
Year-by-year debt coverage analysis for BioLine RX Ltd. For market capitalisation and broader financial context, see BioLine RX Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.72x | ILA-43.87 Million | ILA25.45 Million | ▼ -286.7% |
| 2023 | -0.45x | ILA-22.61 Million | ILA50.70 Million | ▲ +56.6% |
| 2022 | -1.03x | ILA-26.24 Million | ILA25.54 Million | ▲ +42.0% |
| 2021 | -1.77x | ILA-23.57 Million | ILA13.30 Million | ▼ -92.9% |
| 2020 | -0.92x | ILA-23.21 Million | ILA25.26 Million | ▲ +18.2% |
| 2019 | -1.12x | ILA-22.67 Million | ILA20.19 Million | ▲ +30.8% |
| 2018 | -1.62x | ILA-24.19 Million | ILA14.91 Million | ▲ +36.2% |
| 2017 | -2.54x | ILA-20.55 Million | ILA8.08 Million | ▲ +31.5% |
| 2016 | -3.71x | ILA-14.51 Million | ILA3.91 Million | ▲ +3.3% |
| 2015 | -3.84x | ILA-14.17 Million | ILA3.69 Million | ▼ -16.6% |
| 2014 | -3.29x | ILA-14.48 Million | ILA4.40 Million | ▼ -34.4% |
| 2013 | -2.45x | ILA-20.23 Million | ILA8.27 Million | ▼ -13.6% |
| 2012 | -2.15x | ILA-20.11 Million | ILA9.34 Million | ▼ -30.7% |
| 2011 | -1.65x | ILA-11.22 Million | ILA6.81 Million | ▼ -425.9% |
| 2010 | 0.51x | ILA11.46 Million | ILA22.65 Million | — |